On January 29, 2018, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers. This notice is a supplement to the information published on August 18, 2017 regarding changes of an administrative nature.
Requests for withdrawals from the Liste des médicaments and the Liste des ... Read More
News & Events
30
Jan2018
22
Jan2018
PMPRB myth busting (I): The imaginary link between Canadian price controls and R&D expenditures
/ Blog, What's New
The myth perpetuated by government and academics – and echoed in the media – is that the Patented Medicine Prices Review Board’s (PMPRB’s) current price control regime was somehow structured to go easy on patented drug prices in exchange for significant R&D commitments. The upshot being that since the R&D ... Read More
15
Jan2018
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of December 31, 2017:
36 negotiations are currently underway with 5 new files added since the last update of November 30, 2017:
Blincyto (blinatumomab) : Used to treat adult acute lymphoblastic leukemia
Blincyto (blinatumomab) ... Read More
21
Dec2017
On December 12, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 132).
Update on Revised Process for Biosimilars
In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the submission and review process for biosimilars through ... Read More
20
Dec2017
14
Dec2017
TODAY at 1 pm: Government of Canada Officials to Speak on Proposed Regulatory Amendments
/ Canada, What's New
Government of Canada officials will hold a bilingual web-based information session about the proposed regulatory amendments. See the Government of Canada announcement for details on today’s webinar.
11
Dec2017
PMPRB Releases Guidelines Scoping Paper with Overview of Potential New Framework
/ PMPRB, What's New
Following the December 2, 2017 publication of proposed amendments to the Patented Medicines Regulations in Canada Gazette Part I, and the corresponding publication of the Regulatory Impact Assessment Statement, PMPRB has published a Guidelines Scoping Paper providing “…an outline of the PMPRB’s preliminary thoughts on how best to operationalize ... Read More
07
Dec2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of November 30, 2017:
39 negotiations are currently underway with 4 new files added since the last update of October 31, 2017:
Cerdelga (eliglustat): Used to treat Gaucher disease
Cerezyme (imiglucerase): Used to treat ... Read More
05
Dec2017
Health Canada releases proposed PMPRB Price Regulations – The Charge of the Price Brigade
/ Blog, PDCI, What's New
The mandatory public consultation process must be a tiresome inconvenience for Health Canada policy makers. At least that’s the perception from the release of its proposed amendments to the Patented Medicines Regulations (Regulations) and the accompanying Regulatory Impact Assessment Statement (RIAS) published in Canada Gazette Part I last week. Why ... Read More
04
Dec2017
PDCI Webinar: Proposed Amendments to Patented Medicines Regulations – What Patentees Need to Know
/ News, PDCI, PMPRB, Upcoming Events, What's New
Join us for a webinar on Dec 06, 2017 at 2:00 PM EST.
Register now!
Join PDCI’s Founder and Principal Consultant, Neil Palmer on this industry only webinar as he discusses the proposed amendments to the Patented Medicines Regulations as published in Canada Gazette Part 1 on December 2, 2017. What ... Read More